ArticlePreventive medicine2022
Low rates of HPV vaccination and cervical cancer screening: Challenges and opportunities in the context of the COVID-19 pandemic.
Article in Preventive medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Perceptions of HPV vaccination: a qualitative study with adolescents, parents, school staff, and pharmacists.BMC medicine · 2026Article
- The Impact of COVID-19 on Cervical Cancer Screening in Primary Care.Journal of the American Board of Family Medicine : JABFM · 2025Article
- Knowledge and awareness of cervical cancer and prevention measures among female students in Poland: a cross-sectional, decade apart study.Journal of gynecologic oncology · 2025Article
- Early adoption of innovation in HPV prevention strategies: closing the gap in cervical cancer.Ecancermedicalscience · 2024Review
- Empowering Women's Health: Insights Into HPV Vaccination and the Prevention of Invasive Cervical Cancer.Cureus · 2023Review
- Article
- Article
- Article
- Cervical cancer prevention program in Mexico disrupted due to COVID-19 pandemic: Challenges and opportunities.Frontiers in oncology · 2023Article
- Article
- HPV vaccine intention among university students during suspension of active recommendation in Japan.Human vaccines & immunotherapeutics · 2022Article
- Cervical Cancer Prophylaxis-State-of-the-Art and Perspectives.Healthcare (Basel, Switzerland) · 2022Review
- Knowledge, Attitudes and Practices of Women in the UAE Towards Breast and Cervical Cancer Prevention: A Cross-Sectional Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This invited commentary discusses the article by Richards et al. describing differences in rates of on-time HPV vaccination and cervical cancer screening in 2018 among enrollees in different insurance plans. The commentary focuses on the larger problem of low vaccination HPV rates and decreasing cervical cancer screening rates seen across all sectors. We outline challenges posed by the COVID-19 pandemic on HPV vaccination and cervical cancer screening, and discuss opportunities to improve cervical cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.